iCo-007 (formerly known as ISIS 13650) is a second generation antisense compound being developed by iCo for the treatment of various eye diseases caused by the formation of new blood...
- Mechanism
- Curator reviewed
iCo-007 is an antisense inhibitor of c-Raf kinase, an enzyme important in the signal transduction pathway triggered by VEGF as well as other important growth factors. In preclinical studies, antisense inhibition of c-Raf kinase was associated with a reduction in the formation of new blood vessels in the eye, suggesting c-Raf kinase inhibition could be valuable in the treatment of both AMD and diabetic retinopathy.
- Primary indication
- Various eye diseasesCurator reviewed
- Code names
- iCo-007
Resolves to
What you can answer from here — as of April 02, 2025
Which drugs share a target with iCo-007, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account